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Abstract
Background: Adolescents with childhood onset growth hormone deficiency (CO-GHD) require re-evaluation of
their growth hormone (GH) axis on attainment of final height to determine eligibility for adult GH therapy (rhGH).
Aim: Retrospective multicentre review of management of young adults with CO-GHD in four paediatric centres in
Scotland during transition.
Patients: Medical records of 130 eligible CO-GHD adolescents (78 males), who attained final height between 2005
and 2013 were reviewed. Median (range) age at initial diagnosis of CO-GHD was 10.7 years (0.1–16.4) with a
stimulated GH peak of 2.3 μg/l (0.1–6.5). Median age at initiation of rhGH was 10.8 years (0.4–17.0).
Results: Of the 130 CO-GHD adolescents, 74/130(57 %) had GH axis re-evaluation by stimulation tests /IGF-1
measurements. Of those, 61/74 (82 %) remained GHD with 51/74 (69 %) restarting adult rhGH. Predictors of persistent
GHD included an organic hypothalamic-pituitary disorder and multiple pituitary hormone deficiencies (MPHD). Of the
remaining 56/130 (43 %) patients who were not re-tested, 34/56 (61 %) were transferred to adult services on
rhGH without biochemical retesting and 32/34 of these had MPHD. The proportion of adults who were offered rhGH
without biochemical re-testing in the four centres ranged between 10 and 50 % of their total cohort.
Conclusions: A substantial proportion of adults with CO-GHD remain GHD, particularly those with MPHD and most
opt for treatment with rhGH. Despite clinical guidelines, there is significant variation in the management of CO-GHD
in young adulthood across Scotland.
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Background
The transition of care from childhood to adulthood for
many chronic disorders requires a careful coordinated
approach and this is particularly important in growth
hormone deficiency (GHD). Traditionally, children with
childhood onset GHD (CO-GHD) discontinue recombin-
ant human GH therapy (rhGH) after attaining final height.
However, adults with CO-GHD may have increased fat
mass, decreased muscle mass and low bone mineral dens-
ity, as well as reduced cardiac performance, altered lipid
status, reduced physical performance, impaired cognitive
function and reduced well-being [1, 2]. Reports suggest
that these adults may benefit from rhGH [3, 4]. A number
of studies have shown that a high proportion of CO-GHD
patients remain GH deficient as adults especially those
with multiple pituitary hormone deficiencies (MPHD)
and/or structural abnormalities, whereas the majority of
those with idiopathic or isolated GHD no longer have
GHD in adulthood [5–7]. Therefore, after childhood treat-
ment it is necessary to review GH status in order to assess
appropriateness of adult rhGH replacement [8]. However,
the extent of benefit from this therapy may be variable
and the decision to reinstitute rhGH needs to be under-
taken carefully.
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In this context, clinical practice guidelines have been
issued on the subject of transition of care of young
adults with CO-GHD [9–12]. However, the practicalities
of these guidelines as well as the extent to which these
guidelines have been implemented in clinical practice
are unclear. The purpose of this multicentre study was
to understand the variation that may exist in the man-
agement of young adults with CO-GHD after attainment
of final height.
Methods
We reviewed databases from the four specialist endo-
crine centres in Scotland and identified young adults
who had been diagnosed as having CO-GHD and who
had been treated with GH during childhood and had
subsequently reached final height between 2005 and
2013. Study entry criteria were: CO-GHD (low GH peak
response on stimulation test <6.6 μg/l), GH treatment
during childhood, attainment of final height between
2005 and 2013 (height velocity <1 cm/year as defined in
all centres), and evaluation of GH- axis by stimulation
tests and/or IGF-1 levels after withdrawal of GH for at
least one month. Exclusion criteria included: untreated
CO-GHD, GH-treated patients with CO-GHD who have
not yet attained final height. Baseline demographic data
included: aetiology of CO-GHD, age at diagnosis of CO-
GHD, duration of GH treatment, presence of multiple
pituitary hormone deficiencies (MPHD), re-evaluation of
GH axis, and whether adult GH treatment was recom-
menced or not. The persistent GHD after retesting for
four centers was defined as cutoff <5 μg/L GH peak
response for dynamic stimulation testes and/or low
serum IGF-1 levels (<2 SD for age and sex) [9]. IGF-1
level measurement for centres A, B, and D were done
using IDS iSys and centre C measured IGF-1 levels by
immunoassay on the Siemens Immulite. All IGF-1 levels
were corrected for age and sex accordingly.
Statistical analysis
Data were analyzed using Minitab software (Version 16)
with a significance level of <0.05 and are described as
median, ranges and percentage. Additionally, the Mann–
Whitney U–test was used for calculation of significance
of differences between median values. Association with
clinical factors was assessed by Spearman’s rank coeffi-
cient and a positive predictive value (PPV) was calculated
for the identified predictors of persistent GHD.
Results
General characteristics
A total of 142 patients were screened, 130 of whom met
inclusion criteria. The 130 patients (78 male) comprised
of: 70 from centre A, 32 from B, 18 from C and 10 from
D. Table 1 displays the aetiology of CO-GHD. Median
age at diagnosis of CO-GHD was 10.7 years (0.1–16.4)
with an initial stimulated GH peak of 2.3 μg/l (0.1–6.5),
and basal IGF-1 was 74 μg/l (4.0–410.0). Median age at
initiation of rhGH was 10.8 years (0.4–17.0). GH peak
at diagnosis was lower in those with MPHD compared
to IGHD (1.9 μg/l (<0.1–6.4) vs 3.0 μg/l (0.3–6.5)
respectively: p < 0.01).
Re-evaluation of GH axis
A total of 74/130 (57 %) patients with CO-GHD (IGHD=
31 (42 %): MPHD= 43(58 %)) were biochemically retested
at a median age of 18.2 years (14.5–21.3) (with one outlier
patient who was retested at the age of 27.5 years), rhGH
treatment was discontinued at the median age of 16.4 years
(10.8–21.0). Biochemical retesting was performed after a
median period of 0.5 years (0.1–5.6) off rhGH (21/74
(28 %) were retested over period of (0.1–0.3 years) and 34/
74(46 %) over a period of (0.4–5.7 years), with incomplete
data on timing of re-testing in 20/74 (27 %). Median dur-
ation of childhood treatment was 5.3 years (0.4–16.8). At
retesting, the median GH peak was 1.6 μg/l (0.1–23.7) and
IGF-1 was 88.0 μg/l (15.0–631.0). Of those retested, 61/74
(82 %) (32 males) remained GHD and were eligible for
adult rhGH, with 51/61 (84 %) re-starting adult rhGH and
10/61 (16 %) declining therapy although it is possible that
they may have restarted at a later stage. The remaining
13/74 (18 %)(10 males) who were no longer GH deficient
consisted of eight with idiopathic IGHD, two brothers
with central hypothyroidism and normal pituitary MRI,
one with an ectopic pituitary, one with hypogonadism and
Coeliac disease and one with a history of cranial irradi-
ation. Of the 56 of 130 (43 %) cases of CO-GHD who were
not retested 34 (61 %) were transferred from paediatric to
adult services without biochemical retesting during transi-
tion, 12 (21 %) stopped treatment without biochemical re-
evaluation and 10 (18 %) were lost to follow up whilst on
treatment (Fig. 1).
Dynamic function stimulation tests were performed in
40/74 (54 %) patients who were retested, with 35/40
(88 %) of subjects having a low GH peak response <5 μg/l,
with 27/35 of them having severe GHD with a GH peak
response <3 μg/l. Of the remaining 34/74 (46 %) patients
who were retested, IGF-1 levels alone were available and
low enough to confirm GHD (≤ -2 SD for age and gender)
in 19/34 (56 %) of which 15 had MPHD and 4 had IGHD
(organic causes and abnormal pituitary MRI). Two
patients (MPHD) had IGF-1 levels within normal range
on initial retesting (>2 SD for age and gender), but were
confirmed to have GHD following GH stimulation tests.
Reconfirmation of GHD and initiation of adult GH
replacement therapy
Of the 130 with CO-GHD, 34 (26 %) patients continued
adult rhGH without temporary cessation of therapy or
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formal retesting. Of these 34, nine had structural abnor-
malities on MRI, 22 were related to late effects of cancer
therapy and three had unexplained GHD. Of those 34,
31 (91 %) had MPHD (17/32 of them had three or more
additional pituitary hormone deficiencies (PHDs)); and
3/34 (9 %) had IGHD (two with pituitary structural ab-
normalities on MRI and one with tumour related GHD).
These patients were advised to continue rhGH until
their mid-20s.
For patients who were re-tested, GH cut offs for consid-
ering rhGH varied between centres. Not all patients found
to have persistent GHD restarted adult GH therapy despite
low peak GH levels at re-testing. There were four patients
who were found not to have severe GHD with GH peaks
Fig. 1 Study Cohort Flow Chart. (n); number of patients, CO-GHD; childhood onset growth hormone deficiency, IGHD; isolated growth hormone
deficiency, MPHD; multiple-pituitary hormone deficiencies, GH; growth hormone therapy
Table 1 The categories of patients with CO-GHD according to aetiology and centres distribution is shown as (A, B, C, D)
Total number
of cases 130
IGHD MPHD*
48/130 (37 %) 82/130 (63 %)
Congenital n (%) (A,B,C,D) 38/130 (29 %) 12 (8,1,2,1) 26 (14,3,4,5)
-Pituitary axial structural abnormalities (A,B,C,D) 24 9 (6,1,1,1) 15 (6,3,1,5)
-Midline axial structure defects (SOD) (A,B,C,D) 14 3 (2,0,1,0) 11 (8,0,3,0)
Oncology/cranial irradiation n (%) (A,B,C,D) 51/130 (40 %) 8 (5,3,0,0) 43 (18,19,4,2)
- Craniopharyngioma (A,B,C,D) 15 – 15 (6,7,1,1)
- Hematologic malignancies (A,B,C,D) 12 4 (4,0,0,0) 8 (6,0,1,1)
- Medulloblastoma (A,B,C,D) 6 1 (0,1,0,0) 5 (1,4,0,0)
- Other CNS tumors (A,B,C,D) 18 3 (1,2,0,0) 15 (5,8,2,0)
Idiopathica n (%) (A,B,C,D) 15/130 (11 %) 13 (7,1,5,0) 2 (1,1,0,0)
Othersb n (%) (A,B,C,D) 26/130 (20 %) 15 (12,1,1,1) 11 (5,3,2,1)
-Crohn's disease (A,B,C,D) 4 4 (3,0,0,1) –
-Coeliac disease (A,B,C,D) 2 – 2 (0,1,1,0)
-Haematological diseasesc (A,B,C,D) 2 1 (1,0,0,0) 1 (1,0,0,0)
-Other diseasesd (A,B,C,D) 11 8 (6,1,1,0) 3 (0,2,1,0)
-Syndromese(A,B,C,D) 6 2 (2,0,0,0) 4 (3,0,0,1)
-Acquired brain injury (A,B,C,D) 1 – 1 (1,0,0,0)
Data are presented as the numbers of patients and percentages are given in parentheses
*33/82 patients with one additional pituitary hormone deficiency, 17/82 with two additional deficiencies, 19/82 with three and 13/82 with four additional
deficiencies ‘panhypopituitarism’
IGHD, isolated growth hormone deficiency; MPHD, multiple-pituitary hormone deficiencies; SOD, Septo-optic dysplasia
aNormal pituitary MRI, GHD is not associated with other conditions
bNormal pituitary MRI (or no MRI report), but GHD is associated with other conditions
c(Thalassemia, X-linked Sideroblastic Anaemia)
d(Microephaly with learning disability, history of intrauterine growth retardation, gastrochisis with history of small for gestational age, Asthma, joint hypermobility
syndrome, pesudohypoparathyrodism)
e(Charge syndrome, Noonan syndrome, Kallman Syndrome, trisomy 22, Klinefelter's syndrome, Turner's syndrome with GHD)
Ahmid et al. International Journal of Pediatric Endocrinology  (2016) 2016:6 Page 3 of 6
4-5 μg/l (three patients from centre B, one from centre A)
and were not offered rhGH as they did not meet adult
criteria for replacement. However, among those who were
offered rhGH after retesting, one patient with IGHD
(centre C) had a GH peak >5 μg/l (5.5 μg/l).
Variation in the management between centres
There were substantial variations in the management
of CO-GHD between Scottish centres. Re-testing with
stimulation testes and/or IGF-1 levels was found to be
the highest in centre A (68 %), while centre C had the
lowest percentage of retested patients (28 %), although
this did include all IGHD patients from centre C.
Centre B did not retest those with a high likelihood of
permanent GHD (especially those with three or more
additional PHDs) and had the highest percentage of
adults on rhGH without biochemical re-evaluation
(Table 2). A total of 32/130 patients in the cohort had
three or more additional PHDs (Table 3). Of these 32,
14 (44 %) were retested using their IGF-1 levels alone
and all were confirmed to have adult GHD, 17 (53 %)
continued on rhGH without biochemical retesting and
one was lost to follow up whilst on treatment.
Predictors of persistent GHD on re-evaluation
Patients with persistent GHD were diagnosed at an earl-
ier age ((8.4 years (0.3–16.0) vs 11.6 years (7.1–15.5))
and reached final height with re-evaluation of their GH
axis in earlier adolescence ((17.9 years (14.2–21.2) vs
19.3 years (17.3–21.3)) than those who were no longer
GH deficient on retesting. No significant differences in
the other parameters between persistent GHD and non-
persistent GHD were identified at time of diagnosis or
re-evaluation. In this population the peak GH level on
retesting was positively related with the GH peak level at
childhood (r = 0.4, P = 0.02). The number of additional
PHDs was a predictor of a low peak GH on retesting as
all patients with two or more additional PHDs had a
lower GH response (<5 μg/l) at reassessment with a PPV
(93 %). The presence of hypothalamic–pituitary struc-
tural abnormalities has a high PPV (96 %) of persistent
GHD, as of the 25 who were retested, 24 were recon-
firmed with persistent GHD. Similarly, CO-GHD with a
history of cranial irradiation predicted persistent GHD
in adulthood (96 %).
Discussion
Our data confirm that a high proportion (82 %) of the
retested patients with CO-GHD continue to have GHD
as adults. The majority (80 %) of those who remain GH
deficient opted to resume adult GH treatment, however
it is unknown whether they complied with therapy and
for how long they continued with the treatment. It may
also be the case that those adults who were GHD ini-
tially declined to restart rhGH during transition, but
later reconsidered GH therapy. Factors influencing this
decision would be an important area for future studies.
Previous published studies have reported variable esti-
mates of persistent GHD in adulthood ranging from
12.5–90 % [13, 14] but the high incidence of ongoing
GHD in adulthood in our cohort may be attributed to
the large proportion of patients with organic causes for
their GHD. Some of our subjects with MPHD who had
no structural abnormalities on MRI continued to have
GHD, raising the possibility of an underlying genetic
disorder. Similarly, the majority of idiopathic IGHD who
were re-evaluated were GH deficient which may also
indicate an underlying genetic predisposition. These
findings suggest the importance of follow up and regular
assessment of pituitary function in those with a low
probability of persistent GHD, as they may develop other
pituitary hormone deficiencies as previously demonstrated
[15, 16]. On the other hand, some patients who would be
considered as having a moderate to high probability of
persistent GHD (IGHD with structural abnormalities,
patients with MPHD or those with a history of cranial
irradiation) were no longer GH deficient. These findings
demonstrate the limitations in using “at risk” groups to
determine who require re-evaluation of their GH axis and
those who do not.
Our data confirm that while there are no unequivocal
auxological or clinical signs that predict the transiency
Table 2 Management of patients with CO-GHD according to each Scottish centre
All centres A B C D
Total number of patients (n) 130 70 32 18 10
Total number of patients re-tested n (%) 74/130 (57) 48/70 (69) 16/32 (50) 5/18 (28) 5/10 (50)
Persistent GHD n (%) 61/74 (82) 43/48 (90) 12/16 (75) 1/5 (20) 5/5 (100)
Those with persistent GHD who restarted rhGH n (%) 51/61 (83) 35/43 (81) 11/12 (92) 1/1 (100) 4/5 (80)
Total number of patients not-retested n (%) 56/130 (43) 22/70 (31) 16/32 (50) 13/18 (72) 5/10 (50)
Continued adult rhGH therapy without re-testing n (%) 34/56 (61) 7/22 (32) 16/16 (100) 7/13 (54) 4/5 (80)
Lost to follow up whilst on treatment n (%) 10/56 (18) 9/22 (41) 0 0 1/5 (20)
Stopped GH, no re-testing required n (%) 12/56 (21) 6/22 (27) 0 6/13 (46) 0
Data are presented as the numbers of patients and percentages are given in parentheses
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or the persistence of GHD, a history of organic disease,
the presence of two or more additional PHDs [17, 18],
presence of hypothalamic-pituitary structural abnormal-
ities and tumour related organic GHD are strong indica-
tors of persistence GHD [19–22].
In terms of timing of retesting, the current guidelines
suggest that a period from one to three months off rhGH
is sufficient for retesting [9]. Our data show a variable
interval between stopping treatment and reassessment,
with only 28 % of patients off rhGH for less than 3 months.
It is not clear for those who were off rhGH for longer dur-
ation before reassessment whether their stopping rhGH
was for reasons other than re-testing. However, this
prolonged period off rhGH may be associated with detri-
mental effects on somatic bone and body composition
development during transition [23, 24], with recommen-
dations for prompt resumption of rhGH in individuals
with clinical evidence of persistent GHD [25]. Further-
more, a longer interval off rhGH may increase the risk of
being lost to follow up in these already vulnerable patients
and continued follow up around this time is essential [26].
We recommend that in patients who are under the care of
paediatric services, the evaluation of GHD in transition
should be undertaken by the paediatric clinic, ideally in
the context of a joint transition service to improve the
follow up and smooth transfer of adolescents with chronic
endocrine conditions to the adult services as previously
suggested [27].
The principle of offering rhGH during transition for
those who have ongoing severe deficiency was variable be-
tween centres as the cut-offs chosen are variable, though
the majority were in keeping with the guidance suggesting
a GH peak <5 μg/l constituting severe GHD in transition
[9, 10]. Few patients in our cohort declined restarting
adult rhGH, they may be asymptomatic and therefore
reluctant to restart rhGH therapy. Approximately one
third of our subjects were considered to be very likely to
have permanent GHD and therefore continued rhGH
uninterrupted, apart from adjustment to an adult GH
dose. This is in line with current guidelines which recom-
mend that patients with severe congenital or acquired
panhypopituitarism with three or more pituitary hormone
deficiencies or identified genetic mutations may not
require re-evaluation of their GH status; otherwise all
patients with CO-GHD require biochemical re-evaluation
and reconfirmation of GHD during transition before rein-
stituting adult GH replacement therapy [9, 12]. However,
of the 34 patients who continued adult rhGH without
formal retesting, nine had structural abnormalities on
MRI probably were at high risk of ongoing GHD, but
three had unexplained GHD and probably should have
been retested. Furthermore, some centres still retested
those with a high likelihood of permanent GHD, by check-
ing their IGF1 levels, although all were reconfirmed GHD
and resumed rhGH. On these grounds, it seems that no
clear consensus has been reached as to whether or not to
withdraw treatment and retest those at high risk of
permanent GHD. It is also unclear whether those who
continued rhGH without biochemical re-testing were re-
evaluated at a later stage. For those who restarted rhGH,
according to the current guidelines, at completion of
somatic growth (approximately 25–30 years old) further
re-evaluation should be undertaken with the offer of adult
GH replacement therapy and monitoring in accordance
with National Institute for Health and Care Excellence
guidance (NICE) (TA 64 August 2003).
Conclusion
In conclusion, this study not only provided a snapshot of
the differences in management of CO-GHD during
Table 3 Variation in the management of patients with CO-GHD between the four Scottish centres according to GHD categories
Centres A B C D
IGHD MPHD IGHD MPHD IGHD MPHD IGHD MPHD
Total CO-GHD n = 130 [32] 32 38[16] 6 26[10] 8 10[3] 2 8[3]
Retested n = 74 [14] 21 27[13] 4 12[0] 4 1 [0] 2 3[1]
With structural abnormalitiesa 8 13[5] – 2 1 – – –
Tumour relatedb 3 13[8] 2 7 – 1 – 1
Idiopathic/unexplainedc 10 1 2 3 3 – 2 2[1]
Re-confirmed GHD 16 27[13] 3 9[0] 1 0 2 3[1]
Not retested (but on adult rhGH) n = 34 [17] 0 7[2] 2 14[10] 1 6 [3] – 4[2]
With structural abnormalitiesa – – 2 1 1 3 [3] – 1
Tumour relatedb – 5[2] – 12[10] – 3 – 1[1]
Idiopathic/unexplainedc – 2 – 1 – – – 2[1]
Data are presented as number of patients with CO-GHD and [number of patients who have three and more additional pituitary hormones deficiencies
aMRI imaging reported hypothalamic-pituitary axial structural abnormalities
bCranial irradiation
cNormal pituitary MRI/Congenital GHD unexplained (no MRI report)/and/or associated with chronic disease
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transition across Scotland, but it has also enabled us to
identify areas of uncertainty despite there being clinical
practice recommendations. Our data showed a substan-
tial proportion of patients with CO-GHD remain GH
deficient and most opt for rhGH as adults, although not
all patients may require re-evaluation of their GH axis.
This study also raises concerns about follow up of those
who no longer have GHD and patients with GHD who
opted not to resume adult rhGH. The optimal manage-
ment of adolescents with CO-GHD requires continuous
follow up during transition and effective communication
between paediatric and adult services.
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